211 related articles for article (PubMed ID: 34269313)
1. Factors influencing postembolization syndrome in patients with hepatocellular carcinoma undergoing first transcatheter arterial chemoembolization.
He JJ; Yin XX; Wang T; Chen MY; Li XL; Yang XJ; Shao HY
J Cancer Res Ther; 2021 Jul; 17(3):777-783. PubMed ID: 34269313
[TBL] [Abstract][Full Text] [Related]
2. Nausea and vomiting after transcatheter arterial chemoembolization for hepatocellular carcinoma: incidence and risk factor analysis.
Wang SY; Zhu WH; Vargulick S; Lin SB; Meng ZQ
Asian Pac J Cancer Prev; 2013; 14(10):5995-6000. PubMed ID: 24289614
[TBL] [Abstract][Full Text] [Related]
3. Development of a predictive nomogram for postembolization syndrome after transcatheter arterial chemoembolization of hepatocellular carcinoma.
Bai J; Huang M; Zhou J; Song B; Hua J; Ding R
Sci Rep; 2024 Feb; 14(1):3303. PubMed ID: 38332011
[TBL] [Abstract][Full Text] [Related]
4. Fever after transcatheter arterial chemoembolization for hepatocellular carcinoma: incidence and risk factor analysis.
Li CP; Chao Y; Chen LT; Lee RC; Lee WP; Yuan JN; Yen SH; Lee SD
Scand J Gastroenterol; 2008 Aug; 43(8):992-9. PubMed ID: 19086281
[TBL] [Abstract][Full Text] [Related]
5. Risk Factors for Postembolization Syndrome After Transcatheter Arterial Chemoembolization.
Arslan M; Degirmencioglu S
Curr Med Imaging Rev; 2019; 15(4):380-385. PubMed ID: 31989907
[TBL] [Abstract][Full Text] [Related]
6. Short-term efficacy and safety of callispheres drug-loaded microsphere embolization in primary hepatocellular carcinoma.
Li J; Wang N; Shi C; Liu Q; Song J; Ye X
J Cancer Res Ther; 2021 Jul; 17(3):733-739. PubMed ID: 34269307
[TBL] [Abstract][Full Text] [Related]
7. Balloon-Occluded Transcatheter Arterial Chemoembolization (b-TACE) for Hepatocellular Carcinoma Performed with Polyethylene-Glycol Epirubicin-Loaded Drug-Eluting Embolics: Safety and Preliminary Results.
Lucatelli P; Ginnani Corradini L; De Rubeis G; Rocco B; Basilico F; Cannavale A; Nardis PG; Corona M; Saba L; Catalano C; Bezzi M
Cardiovasc Intervent Radiol; 2019 Jun; 42(6):853-862. PubMed ID: 30843093
[TBL] [Abstract][Full Text] [Related]
8. Transcatheter arterial chemoembolization as primary treatment for hepatocellular carcinoma.
Rose DM; Chapman WC; Brockenbrough AT; Wright JK; Rose AT; Meranze S; Mazer M; Blair T; Blanke CD; Debelak JP; Pinson CW
Am J Surg; 1999 May; 177(5):405-10. PubMed ID: 10365881
[TBL] [Abstract][Full Text] [Related]
9. A Predictive Model for Postembolization Syndrome after Transarterial Hepatic Chemoembolization of Hepatocellular Carcinoma.
Khalaf MH; Sundaram V; AbdelRazek Mohammed MA; Shah R; Khosla A; Jackson K; Desai M; Kothary N
Radiology; 2019 Jan; 290(1):254-261. PubMed ID: 30299233
[TBL] [Abstract][Full Text] [Related]
10. Incidence and risk factors of contrast-induced nephropathy after transcatheter arterial chemoembolization in hepatocellular carcinoma.
Aoe M; Kanemitsu T; Ohki T; Kishi S; Ogura Y; Takenaka Y; Hashiba T; Ambe H; Furukawa E; Kurata Y; Ichikawa M; Ohara K; Honda T; Furuse S; Saito K; Toda N; Mise N
Clin Exp Nephrol; 2019 Sep; 23(9):1141-1146. PubMed ID: 31183589
[TBL] [Abstract][Full Text] [Related]
11. How to prophylactically alleviate postembolization syndrome following transarterial chemoembolization?: Protocol of a double blinded, randomized, placebo-controlled trial.
Pan Y; Chang R; He Z; Hong M
Medicine (Baltimore); 2021 Apr; 100(14):e25360. PubMed ID: 33832116
[TBL] [Abstract][Full Text] [Related]
12. Polyethylene Glycol Epirubicin-Loaded Transcatheter Arterial Chemoembolization Procedures Utilizing a Combined Approach with 100 and 200 μm Microspheres: A Promising Alternative to Current Standards.
Lucatelli P; Argirò R; De Rubeis G; Rocco B; Corradini SG; Corona M; Nardis PG; Saba L; Mennini G; Fiorentino F; Corsi A; Catalano C; Bezzi M
J Vasc Interv Radiol; 2019 Mar; 30(3):305-313. PubMed ID: 30713031
[TBL] [Abstract][Full Text] [Related]
13. The safety and efficacy of balloon-occluded transcatheter arterial chemoembolization for hepatocellular carcinoma refractory to conventional transcatheter arterial chemoembolization.
Kim PH; Gwon DI; Kim JW; Chu HH; Kim JH
Eur Radiol; 2020 Oct; 30(10):5650-5662. PubMed ID: 32409860
[TBL] [Abstract][Full Text] [Related]
14. Determination of risk factors for fever after transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma.
Li J; Shi C; Shi J; Song J; Wang N
Medicine (Baltimore); 2021 Nov; 100(44):e27636. PubMed ID: 34871232
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of Drug-Eluting Beads Transarterial Chemoembolization by CalliSpheres
Sun J; Zhou G; Xie X; Gu W; Huang J; Zhu D; Hu W; Hou Q; Shi C; Li T; Zhang X; Ji W; Ying S; Peng Z; Zhou J; Yu Z; Ji J; Du H; Guo X; Fang J; Han J; Xu H; Sun Z; Yu W; Shao G; Wu X; Hu H; Li L; Zheng J; Luo J; Chen Y; Cao G; Hu T
Oncol Res; 2020 Feb; 28(1):75-94. PubMed ID: 31558180
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of dexamethasone and N-acetylcysteine combination in preventing post-embolization syndrome after transarterial chemoembolization in hepatocellular carcinoma.
Simasingha N; Tanasoontrarat W; Claimon T; Sethasine S
World J Gastroenterol; 2023 Feb; 29(5):890-903. PubMed ID: 36816622
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of drug-eluting bead-transcatheter arterial chemoembolization using 100-300 μm versus 300-500 μm CalliSpheres microspheres in patients with advanced-stage hepatocellular carcinoma.
Yang T; Qin W; Sun X; Wang Y; Wu J; Li Z; Ji F; Zhang L; Liu W
J Cancer Res Ther; 2020; 16(7):1582-1587. PubMed ID: 33565503
[TBL] [Abstract][Full Text] [Related]
18. Prediction of postembolization syndrome after transarterial chemoembolization of hepatocellular carcinoma and its impact on prognosis.
Roehlen N; Stoehr F; Müller L; Luxenburger H; Gairing SJ; Reincke M; Schultheiss M; Berisha F; Weinmann A; Foerster F; Marquardt JU; Thimme R; Galle PR; Bettinger D; Kloeckner R
Hepatol Commun; 2023 Oct; 7(10):. PubMed ID: 37756031
[TBL] [Abstract][Full Text] [Related]
19. Clinical significance and risk factors of postembolization fever in patients with hepatocellular carcinoma.
Jun CH; Ki HS; Lee HK; Park KJ; Park SY; Cho SB; Park CH; Joo YE; Kim HS; Choi SK; Rew JS
World J Gastroenterol; 2013 Jan; 19(2):284-9. PubMed ID: 23345952
[TBL] [Abstract][Full Text] [Related]
20. Post-embolization syndrome as an early predictor of overall survival after transarterial chemoembolization for hepatocellular carcinoma.
Mason MC; Massarweh NN; Salami A; Sultenfuss MA; Anaya DA
HPB (Oxford); 2015 Dec; 17(12):1137-44. PubMed ID: 26374137
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
